DALE FULLER: Open Payments
NPI 1255462735 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,638 in 82 payments from 20 companies in 2025. Trend: 2023 $2,693 · 2024 $2,720 · 2025 $3,638
Food & beverage: $2,230Consulting: $1,215Travel & lodging: $193
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $1,863 |
| ABBVIE INC. | 24 | $541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $261 |
| Ipsen Biopharmaceuticals, Inc | 5 | $228 |
| QOL Medical, LLC | 4 | $139 |
| Janssen Biotech, Inc. | 7 | $122 |
| GENZYME CORPORATION | 2 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
Products named: REZDIFFRA, IQIRVO, CREON, RINVOQ, GATTEX, SKYRIZI, Sucraid, DUPIXENT.
Industry payments across TX — which companies pay providers there.
